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Introduction
Th  e bony skeleton enables locomotive activity, the 
storage of calcium, and the harboring of hematopoietic 
stem cells (HSCs). Th   is multifunctional organ is charac-
terized by calciﬁ   ed hard tissue composed of type I 
collagen and highly organized deposits of calcium phos-
phate [1]. Although bone superﬁ   cially seems to be 
metabolically inert, it is, in fact, restructured at such a 
high speed that approximately 10% of the total bone 
content is replaced each year in adult vertebrates. Th  is 
process, called bone remodeling, is dependent on the 
dynamic balance of bone formation and resorption, 
which are mediated by osteoblasts and osteoclasts, 
respectively. A delicate regulation of this process is 
requisite for normal bone homeostasis, and an imbalance 
is often related to metabolic bone diseases in humans [2].
Accumulating evidence has indicated that the immune 
and skeletal systems share a number of regulatory 
molecules, including cytokines, receptors, signaling mole-
cules, and transcription factors. Furthermore, immune 
cells are formed and HSCs are maintained in the bone 
marrow, where they interact with bone cells. Th  erefore, 
the evidence that the physiology and pathology of one 
system might aﬀ  ect those of the other is compelling and 
the term osteoimmunology was coined to cover these 
overlapping scientiﬁ  c ﬁ  elds. Th   e most typical example of 
the interaction between the skeletal and immune systems 
is seen in the abnormal or prolonged activation of the 
immune system (or both) in autoimmune diseases such 
as rheumatoid arthritis (RA), which is characterized by 
progressive multiple joint destruction. Since autoreactive 
T lymphocytes are considered to play a key role in the 
pathogenesis of RA, attention must be paid to the 
relationship between osteoclast-mediated bone destruc-
tion and aberrant adoptive immune responses in order to 
develop eﬀ  ective therapeutic strategies against RA. Here, 
we summarize recent progress in the understanding of 
the relationship between bone and the adaptive immune 
system in arthritis by focusing mainly on osteoclasts and 
osteoclastogenic helper T cells, Th  17  cells.
Osteoclasts and bone destruction
The role of RANK/RANKL in osteoclastogenesis
Osteoclasts are large, multinucleated cells formed by the 
fusion of precursor cells of monocyte/macrophage lineage 
[2]. Mature osteoclasts degrade bone matrix proteins by 
secreting proteolytic enzymes, such as cathepsin K and 
matrix metalloproteinase, and decalcify the inorganic 
components of bone by releasing hydrochloric acid. In 
the late 1980s, an in vitro osteoclast formation system 
that uses a system of culturing bone marrow-derived 
cells of monocyte/macrophage lineage together with 
osteoclastogenesis-supporting cells such as osteoblasts 
was established [3,4]. Th  ese supporting mesenchymal 
cells provide certain factors that are necessary for osteo-
clast diﬀ   erentiation [5]. Analysis of op/op mice with 
osteo  petrosis revealed one of these essential factors to be 
macrophage colony-stimulating factor (M-CSF) [6]. M-
CSF stimulation alone, however, does not induce the 
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apoptotic molecule Bcl-2 partially rescues the osteo-
petrotic phenotype of the op/op mice [7], suggesting that 
M-CSF is a survival factor for osteoclast precursor cells. 
Ultimately, in 1998, Yasuda and colleagues [8] and Lacey 
and colleagues [9] did clone the long-sought ligand 
mediat  ing the essential signal for osteoclast diﬀ  eren-
tiation; this ligand was called ODF and osteoprotegerin 
ligand, respectively. Interestingly, this cytokine, which 
belongs to the tumor necrosis factor (TNF) family, was 
shown to be identical to receptor activator of nuclear 
factor-κB ligand (RANKL) and TNF-related activation-
induced cytokine (TRANCE), both of which had been 
cloned in the immune system [10,11]. Th  e cloning of 
ODF (RANKL, hereafter) enabled investi  gation of the 
diﬀ  erentiation process in a sophisticated culture system 
employing recombinant RANKL and M-CSF [12].
Th  e receptor for RANKL is RANK, a type I trans-
membrane protein that possesses a high homology with 
CD40. RANK is expressed on osteoclast precursor cells 
and mature osteoclasts, and the binding of RANKL to 
RANK is inhibited by the decoy receptor osteoprotegerin 
(OPG) [13,14]. In bone, RANKL is expressed by osteo-
clastogenesis-supporting cells, including osteoblasts, in 
response to osteoclastogenic factors, such as 1,25- 
dihydroxyvitamin D3, prostaglandin E2, and para  thyroid 
hormone, and is a crucial determinant of the level of 
bone resorption in vivo [5,12]. Mice with a disruption of 
either  Rank or Rankl exhibit severe osteopetrosis 
accompanied by a tooth eruption defect resulting from a 
complete lack of osteoclasts [15-17]. In contrast, mice 
lacking Opg exhibit a severe form of osteoporosis caused 
by both an increased number and enhanced activity of 
osteoclasts [18,19]. Th   ese genetic ﬁ  ndings  clearly 
demonstrate that RANK/RANKL signaling is essential 
for osteoclasto  genesis in vivo. Furthermore, mutations in 
RANK, RANKL, and OPG have been identiﬁ  ed in human 
patients with bone disorders such as familial expansile 
osteolysis, autosomal recessive osteopetrosis, and 
juvenile Paget’s disease of bone, respectively [20-23].
RANKL signaling
Th  e ligation of RANK with RANKL results in trimeri-
zation of RANK and recruitment of adaptor molecules 
such as the TNF receptor-associated factor (TRAF) 
family of proteins, among which TRAF6 has been shown 
to be the major adaptor molecule [24,25]. TRAF6 
trimerizes upon RANK stimulation and activates nuclear 
factor-κB (NF-κB) and mitogen-activated protein 
kinases, including Jun N-terminal kinase (JNK) and p38. 
RANK also activates the transcription-factor complex, 
activator protein 1 (AP-1), through the induction of its 
component c-Fos [26]. Th  e induction mechanism of c-
Fos is dependent on the activation of Ca2+/
calmodulin-dependent protein kinase IV (CaMKIV) and 
cyclic adenosine mono  phosphate responsive-element-
binding protein (CREB) [27] as well as the activation of 
NF-κB [28]. Importantly, RANKL speciﬁ  cally  and 
potently induces nuclear factor of activated T cells 
cytoplasmic 1 (NFATc1), the master regulator of 
osteoclast diﬀ  eren  tiation, and this induction is dependent 
on both the TRAF6 and c-Fos pathways [29]. Th  e 
activation of NFAT is mediated by a speciﬁ  c phosphatase, 
calcineurin, which is activated by calcium-calmodulin 
signaling. Th  e  NFATc1 promoter contains NFAT-binding 
sites, and NFATc1 speciﬁ   cally autoregulates its own 
promoter during osteoclasto  genesis, thus enabling the 
robust induc  tion of NFATc1 [30]. Th  e essential role of 
NFATc1 has been conclusively demonstrated by genetic 
experi  ments [30-32]. NFATc1 regulates a number of 
osteoclast-speciﬁ  c genes, such as cathepsin K, tartrate-
resistant acid phosphatase (TRAP), calcitonin receptor, 
osteoclast-associated receptor (OSCAR), and β3 integrin, 
in cooperation with other transcription factors such as 
AP-1, PU.1, micro  phthalmia-associated transcription 
factor (MITF), and CREB (Figure 1).
During osteoclastogenesis, activation of calcium signal-
ing is dependent on costimulatory receptors for RANK, 
which are immunoglobulin-like receptors, such as OSCAR 
and triggering receptor expressed in myeloid cells-2 
(TREM-2). Th  ese receptors associate with the adaptor 
molecules Fc receptor common γ subunit (FcRγ) and 
DNAX-activating protein 12 (DAP12), transducing 
signals by the phosphorylation of immunoreceptor tyrosine-
based activation motifs (ITAMs) within the adaptor 
proteins, which, in turn, recruit  the spleen tyrosine 
kinase (Syk) [33,34] (Figure 1). As shown recently, Tec 
family tyrosine kinases (Tec and Btk) activated by RANK 
cooperate with Syk to induce eﬃ   cient phosphorylation of 
phospholipase Cγ (PLCγ), which induces the release of 
calcium from the endoplasmic reticulum through the 
generation of inositol trisphosphate [35]. Although a 
series of genetically modiﬁ  ed mice has clearly shown that 
ITAM-mediated signals are essential for osteoclasto-
genesis, the ligands for the costimulatory receptors remain 
to be identiﬁ  ed [33-35].
Mechanism of bone destruction in rheumatoid 
arthritis
The essential role of osteoclasts in bone destruction in 
rheumatoid arthritis
Th  e bone destruction observed in the joints of patients 
with RA presents a challenging clinical problem. In the 
early 1980s, researchers observed osteoclast-like cells at 
the bone destruction sites [36], but it was not until 
RANKL was cloned that the importance of osteoclasts 
became generally accepted. We previously demonstrated 
eﬃ     cient osteoclast formation in synovial cell cultures 
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expression of RANKL was detected speciﬁ  cally in the 
synovium of patients with RA [38,39]. Recent studies 
have provided further direct genetic evidence: 
RANKL-deﬁ   cient mice, which lack osteoclasts, were 
protected from bone destruction in an arthritis model 
induced by serum transfer [40]. Bone erosion was not 
observed in osteopetrotic Fos−/− mice, even when they 
Figure 1. Signaling cascades during osteoclastogenesis. Receptor activator of nuclear factor-κB ligand (RANKL)-RANK binding results in the 
recruitment of tumor necrosis factor receptor-associated factor 6 (TRAF 6), which activates nuclear factor-κB (NF-κB) and mitogen-activated protein 
kinases. RANKL also stimulates the induction of c-Fos through NF-κB and Ca2+/calmodulin-dependent protein kinase IV (CaMKIV). NF-κB and c-Fos 
are important for the robust induction of nuclear factor of activated T cells cytoplasmic 1 (NFATc1). Several costimulatory receptors associate with 
the immunoreceptor tyrosine-based activation motif (ITAM)-harboring adaptors, Fc receptor common γ subunit (FcRγ), and DNAX-activating 
protein 12 (DAP12): osteoclast-associated receptor (OSCAR) and triggering receptor expressed in myeloid cells 2 (TREM2) associate with FcRγ, 
and signal-regulatory protein β1 (SIRPβ1) and paired immunoglobulin-like receptor-A (PIR-A) associate with DAP12. RANK signaling and ITAM 
signaling cooperate to phosphorylate phospholipase Cγ (PLCγ) and activate calcium signaling, the latter of which is critical for the activation and 
autoamplifi  cation of NFATc1. Tec family tyrosine kinases (Tec and Btk) activated by RANK are important for the formation of the osteoclastogenic 
signaling complex composed of Tec kinases, B-cell linker (BLNK)/SH2 domain-containing leukocyte protein of 76 kDa (SLP76) (activated by ITAM-
spleen tyrosine kinase, or Syk), and PLCγ, all of which are essential for the effi   cient phosphorylation of PLCγ. AP-1, activator protein 1; CREB, cyclic 
adenosine monophosphate responsive-element-binding protein; MITF, microphthalmia-associated transcription factor; TRAP, tartrate-resistant acid 
phosphatase.
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erosive arthritis spontaneously [41]. In the two cases, a 
similar level of inﬂ  ammation was observed, indicating 
that RANKL and osteoclasts are indispensable for the 
bone loss but not the inﬂ  ammation. Consistent with this, 
anti-RANKL and anti-osteoclast therapies have been 
shown to be beneﬁ  cial in the treatment of bone damage 
in animal models of arthritis [42,43]. Inﬂ  ammatory cyto-
kines such as TNF-α, interleukin-1 (IL-1), and IL-6 have 
a potent capacity to induce RANKL expression on 
synovial ﬁ  broblasts/osteoblasts and to facilitate RANKL 
signaling, thus contributing directly to the bone 
destruction process. In particular, TNF-α is considered of 
special importance since anti-TNF therapy reduces bone 
erosion as well as inﬂ  ammation [44].
Eff  ect of T cells on osteoclastogenesis
As inﬁ  ltration of T cells into the synovium is a patho-
logical hallmark of RA, it is vital to address how T-cell 
immunity is linked to the enhanced expression of 
RANKL and eventual osteoclastic bone resorption. More 
speciﬁ   cally, as RANKL is known to be expressed in 
activated T cells, it is important to determine whether 
this source of RANKL can directly induce osteoclast 
diﬀ  erentiation. In 1999, Kong and colleagues [42] showed 
that the RANKL expressed on activated T cells acts 
directly on osteoclast precursor cells and induces osteo-
clasto genesis  in vitro. Horwood and colleagues [45] 
reported that osteoclastogenesis could be induced in 
vitro by activated T cells. However, it is important to note 
that T cells produce various cytokines, including inter-
feron-γ (IFN-γ), IL-4, and IL-10, which exert potent 
inhibitory eﬀ  ects on osteoclast diﬀ  erentiation [2]. In the 
former study, the T cells were ﬁ  xed by formaldehyde and 
thus were unable to release any humoral factors [42]. In 
the latter study, the T cells and osteoclast precursor cells 
were derived from diﬀ  erent species, suggesting that the 
eﬀ  ect of cytokines would, in all likelihood, be much lower 
than that on cells of the same species [45]. Th  e  question 
then arises as to how T-cell cytokines other than RANKL 
aﬀ  ect osteoclast diﬀ  erentiation.
Upon activation, naïve CD4+ T cells diﬀ  erentiate into 
diﬀ  erent lineages of helper T (Th   ) cells, depending on the 
cytokine milieu [46]. Th   1 and Th   2 cells are traditionally 
thought to be the major subsets generated upon antigenic 
stimulation. Th  1 cells, which are induced by IL-12, 
produce mainly IFN-γ and are involved in cellular 
immunity; Th   2 cells produce mainly IL-4, IL-5, and IL-10 
and contribute to humoral immunity. RA was previously 
considered to be a disease in which the Th  1-Th  2  balance 
is skewed toward Th  1. However, IFN-γ is not highly 
expressed in the joints of patients with RA [47]. Notably, 
IFN-γ strongly inhibits osteoclastogenesis, even at minute 
concentrations, through ubiquitin-proteasome-mediated 
degradation of TRAF6 [48]. Moreover, the severity of 
collagen-induced arthritis was reported to be exaggerated 
in the absence of IFN-γ signaling [49,50], suggesting that 
Th   1 cells are not linked to bone damage in arthritis.
Th17 cells function as osteoclastogenic Th cells
It is worthwhile to deﬁ  ne what is believed to be a very 
rare but pathologically important Th   cell subset that is 
responsible for abnormal bone resorption as osteo  clasto-
genic Th   cells. Previous investigations in our laboratory 
together with other studies on synovial T cell in RA have 
clariﬁ  ed the characteristics of osteoclastogenic Th    cells in 
autoimmune arthritis [51]. First, osteoclastogenic Th   
cells do not produce a large amount of IFN-γ. Second, 
they trigger both local inﬂ  am  mation and the production 
of inﬂ  ammatory cytokines that induce RANKL ex  pres-
sion on synovial ﬁ  broblasts. Th  ird, osteoclasto  genic Th   
cells express RANKL and might thereby participate 
directly in accelerated osteo  clastogenesis. Because these 
Th    cells have such osteoclastogenic characteristics, they 
can tip the balance in favor of osteoclastogenesis 
synergistically.
Th  17 cells have recently been identiﬁ   ed as a new 
eﬀ  ector Th    cell subset characterized by the production of 
proinﬂ   ammatory cytokines, including IL-17, IL-17F, 
IL-21, and IL-22. Th   17 cell diﬀ  erentiation is induced by 
the combination of IL-6 and transforming growth factor-
β (TGF-β). IL-23 is dispensable for the lineage commit-
ment of Th  17 cells but is required for the growth, 
survival, and eﬀ   ector functions of Th  17 cells [52,53]. 
Importantly, this unique subset plays a critical role in 
host defense against certain extracellular pathogens and 
also contributes to the pathogenesis of various auto-
immune diseases [53]. Recent data from our laboratory 
indicate that Th  17 cells represent the long sought-after 
osteoclastogenic Th   -cell subset, fulﬁ  lling all of the criteria 
mentioned above [54]. IL-17 induces RANKL on 
osteoclastogenesis-supporting mesenchymal cells, such 
as osteoblasts and synovial ﬁ  broblasts [55]. IL-17 also 
enhances local inﬂ  ammation and increases the produc-
tion of inﬂ  ammatory cytokines, which further promote 
RANKL expression and activity. Th  erefore, the inﬁ  ltra-
tion of Th   17 cells into the inﬂ  ammatory lesion is the link 
between the abnormal T-cell response and bone damage 
(Figure 2).
Eff  ects of regulatory T cells on osteoclastogenesis
CD4+ CD25+ regulatory T (Treg) cells are a specialized 
T-cell subset that engages in the maintenance of 
immunological self-tolerance and immune homeostasis, 
as evidenced by the development of severe autoimmune 
disease, allergy, and immunopathology in humans and 
mice with a mutation of forkhead box P3 (Foxp3), a 
master regulator for the Treg cell lineage [56]. Treg cells 
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naturally occurring Treg cells generated in the thymus 
and FoxP3+ Treg cells induced by antigen stimulation in a 
milieu rich in TGF-β in the periphery. Although the 
diﬀ  erences and similarities between these two popu  la-
tions are yet to be fully elucidated, both have been con-
sidered to be essential for immune homeostasis. Notably, 
Th   17 cells and Treg cells are reciprocally regulated during 
diﬀ   erentiation but exert the opposite eﬀ   ects on auto-
immunity, and the balance between these populations is 
associated with inﬂ  ammation and autoimmune diseases 
[53,56]. In many studies, Treg cells were found in high 
numbers within joint ﬂ  uid from patients with RA [57-59]. 
However, Treg cells in joint ﬂ  uid from patients with RA 
failed to suppress eﬀ  ector T-cell proliferation or cytokine 
production. Th  is is because inﬂ  ammatory  cytokines, 
includ  ing IL-6 and TNF-α, attenuate Treg function. 
Eﬀ  ector T cells in joint ﬂ  uid were also reported to be 
resistant to suppression by Treg cells. In addition, serum 
markers of bone resorption such as C-terminal 
telo  peptide of type I collagen inversely correlated with 
the number of CD4+CD25+ Treg cells in peripheral blood 
of healthy control and RA patients [60]. Th   us, it is of key 
interest whether Treg cells aﬀ  ect  inﬂ  ammatory-asso-
ciated bone destruction. Several groups have reported 
the inhibitory eﬀ  ect of Treg cells on osteoclastogenesis 
and bone resorp  tion, but no consensus regarding their 
inhibitory mechanisms has been established. Kim and 
colleagues [61] reported that the human CD4+CD25+ 
Treg cells isolated from peripheral blood mononuclear 
cells (PBMCs) suppress osteoclast diﬀ   erentiation in a 
cytokine-dependent manner and proposed that TGF-β 
and IL-4 are required for the suppressive function of Treg 
cells. Zaiss and colleagues [62] demonstrated the inhi  bi-
tory eﬀ  ect of CD4+CD25+ Treg cells puriﬁ  ed from mouse 
spleen on osteoclast diﬀ  erentiation. However, the authors 
showed that CD4+CD25+ Treg cells inhibit osteoclasto-
genesis partially via IL-4 and IL-10 production but mainly 
through cell-to-cell contact via cytotoxic T lympho  cyte 
antigen 4. It is notable that wild-type Treg cells failed to 
Figure 2. Regulation of osteoclast diff  erentiation by T cells in rheumatoid arthritis. Interleukin (IL)-17-producing helper T (Th17) cells have 
stimulatory eff  ects on osteoclastogenesis and play an important role in the pathogenesis of rheumatoid arthritis through IL-17, whereas Th1 and 
Th2 cells have inhibitory eff  ects on osteoclastogenesis through interferon-γ (IFN-γ) and IL-4, respectively. IL-17 not only induces receptor activator 
of nuclear factor-κB ligand (RANKL) on synovial fi  broblasts of mesenchymal origin but also activates local infl  ammation, leading to the upregulation 
of proinfl  ammatory cytokines, such as tumor necrosis factor-α (TNF-α), IL-1, and IL-6. These cytokines activate osteoclastogenesis by either acting 
directly on osteoclast precursor cells or inducing RANKL on synovial fi  broblasts. Th17 cells also express RANKL on their cellular membrane, and this 
partly contributes to the enhanced osteoclastogenesis. RANK, receptor activator of nuclear factor-κB.
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monocytes [63]. A decrease in osteo  clast number and 
bone resorption was observed after transfer of 
CD4+CD25+ Treg cells into Rag1-deﬁ  cient mice, indicat-
ing that Treg cells could directly block osteoclastogenesis 
without engaging eﬀ  ector T cells [63]. Furthermore, Luo 
and colleagues [64] recently reported that human PBMC-
derived CD4+CD25+ Treg cells suppress osteoclasto-
genesis and bone resorption in a TGF-β1 and IL-10 
cytokine-dependent manner. Since TGF-β, IL-10, and 
IL-4 are cytokines that are well known to inhibit osteo-
clastogenesis, these cytokines produced by Treg cells may 
be involved, at least partially, in the suppressive function 
of Treg cells on osteoclastogenesis. In all studies by these 
three groups, Treg cells were activated before coculture 
experiments, but their culture conditions varied, and this 
may cause the diﬀ  erence among their results. Zaiss and 
colleagues [63] also reported increased bone mass and 
partial protection from bone loss after ovariectomy in 
Foxp3 transgenic mice. Foxp3+ Treg cells have been 
shown to protect against local and systemic bone 
destruction in the mouse model of TNF-α-induced 
arthritis [60]. It is likely that, taken as a whole, Foxp3+ 
Treg cells exert inhibitory eﬀ   ects on inﬂ  ammatory-
associated bone destruction, but it is important to 
consider the possibility that the charac  ter  istics of Treg 
cells are aﬀ  ected by the speciﬁ  c micro  environment such 
as autoimmune inﬂ   ammation, as described above. 
Additional studies would be needed to determine how 
Treg cells aﬀ   ect osteoclast-mediated bone destruction 
under inﬂ  ammatory conditions.
The involvement of B cells in bone destruction
B cells and antibodies make up the body’s humoral 
immune response. B cells develop within bone marrow 
with the support of the stromal cells and the osteoblast 
lineage cells via various growth factors and cytokines, 
and are released into the blood and lymphatic systems. In 
the sera of most patients with RA, a variety of auto-
antibodies such as rheumatoid factor and anti-cyclic 
citrullinated peptide antibodies can be detected [65]. Th  e 
clinical beneﬁ  t of the treatment of anti-CD20 antibody, 
rituximab, supports the notion that B cell-mediated 
immune responses contribute to the pathogenesis of RA 
[65,66]. However, there are conﬂ  icting data on the role of 
B cells on bone remodeling: whereas some reported that 
activated B cells have the potential to promote osteo-
clastogenesis via RANKL expression [67,68], others 
insisted that B cells have an inhibitory eﬀ  ect on osteo-
clastogenesis through TGF-β or IFN-γ production 
[69,70]. Weitzmann and colleagues [71] reported that 
μMT heavy chain-deﬁ  cient mice, which lack mature B 
cells, are osteoporotic. Th   e authors proposed that B cells 
are critical regulators of physiological bone turnover by 
secreting OPG and that T cells promote enhanced OPG 
secretion by activated B cells via CD40/CD40L costimu-
lation. Interestingly, T cell-deﬁ  cient nude mice, CD40-
deﬁ   cient mice, and CD40L-deﬁ   cient mice displayed 
osteo  porosis and diminished bone marrow OPG produc-
tion [71]. However, the other group reported that neither 
μMT-deﬁ   cient mice nor Rag1-deﬁ   cient mice have an 
obvious bone phenotype [72]. Th  us, the role of B-cell 
lineages in physiological bone remodeling has not been 
ﬁ  rmly established.
IL-7, a major growth factor for B cells, has been 
reported to be upregulated under inﬂ  ammatory condi-
tions and during estrogen deﬁ  ciency [73,74]. Suda and 
colleagues [75] reported that systemic administration of 
IL-7 induced bone loss, which was similar to that of 
ovariectomized mice, and that IL-7Ra-deﬁ  cient mice had 
increased bone mass. Th   e authors proposed that 
increased B lymphopoiesis due to induction of IL-7 by 
estrogen deﬁ   ciency may be involved in the elevated 
osteoclastogenesis. On the other hand, Weitzmann and 
colleagues [76] reported the other eﬀ  ect of IL-7 on bone 
metabolism; IL-7 promotes osteoclastogenesis by up-
regu  lating T cell-derived osteoclastogenic cytokines, 
including RANKL. Indeed, IL-7 administration did not 
induce bone loss in T cell-deﬁ  cient nude mice [77]. In 
contrast, Lorenzo and colleagues [78] reported that IL-7 
inhibited osteoclast formation in bone marrow culture 
and that IL-7 deﬁ  ciency caused increased osteoclasto-
genesis and decreased trabecular bone mass in vivo [79]. 
Wild-type and IL-7-deﬁ  cient mice lose similar amounts 
of trabecular bone mass after ovariectomy. Consideration 
of the various eﬀ  ects of IL-7 on diﬀ  erent target cells will 
be required to deﬁ  ne the precise role of IL-7-mediated B 
lymphopoiesis on bone remodeling.
Kawai and colleagues [80] reported that, in case of 
bone destruction in periodontal disease, RANKL was 
highly expressed by activated B cells isolated from 
gingival tissues of patients. Furthermore, it has been 
recently reported that, after injection of lipopolysac-
charide (LPS) into mouse gingival, alveolar bone destruc-
tion was more highly induced in B cell-reconstituted 
severe combined immunodeﬁ  ciency (SCID) mice than in 
SCID mice and that LPS-stimulated B cells enhanced 
osteoclast diﬀ  erentiation by producing TNF-α in vitro 
[81]. Th   ese reports suggested that activated B cells have 
stimu latory  eﬀ  ects on bone destruction under inﬂ  am-
matory conditions such as periodontitis, but further 
studies are needed to determine how B cell-mediated 
immune responses are directly involved in the osteoclast 
activation in RA.
Mechanisms involved in Th17 cell diff  erentiation
Th  e  Th   17 cell subset has emerged as an attractive thera-
peutic target for both inﬂ   ammation and bone 
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molecular mechanism underlying Th  17 development in 
order to develop novel therapeutic strategies.
ROR nuclear receptors in Th17 development
Th   cell diﬀ  erentiation is initiated by the T-cell receptor 
signal in combination with other cytokine receptor signals. 
Th   ese signals induce the activation of speciﬁ  c transcrip-
tion factors to promote lineage-speciﬁ  c cytokine produc-
tion [46]. For example, the T-box-containing protein 
expressed in T cells, which is activated by IL-12 and 
IFN-γ, is required for Th  1 cell diﬀ  erentiation. Th  2 cell 
diﬀ   erentiation requires the function of the GATA-
binding protein 3, which is induced by the IL-4-activated 
signal transducer and activator of transcription (Stat) 6.
Soon after the discovery of Th  17 cells, Littman and 
colleagues [82] reported that retinoid-related orphan 
receptor (ROR) γt is selectively expressed in Th  17 cells 
and is required for Th  17 cell diﬀ  erentiation.  RORγt 
expression is induced by the combination of IL-6 and 
TGF-β through Stat3. Furthermore, RORγt deﬁ  ciency 
was shown to lead to an impairment of Th  17 cell 
diﬀ  erentiation both in vitro and in vivo. A subsequent 
study by Dong and colleagues [83] showed that another 
ROR family member, RORα, is highly induced during 
Th  17 cell diﬀ  erentiation in a Stat3-dependent manner. 
Although RORα deletion in mice had only a minimal 
eﬀ  ect on IL-17 production, the deﬁ  ciency of both RORα 
and RORγt completely abolished IL-17 production and 
protected mice from experimental autoimmune 
encephalo  myelitis (EAE), a mouse model of multiple 
sclerosis. Th   us, RORγt and RORα have redundant func-
tions, but RORγt seems to be the major player in Th  17 
cell diﬀ  erentiation. Although the mecha  nisms by which 
the ROR nuclear receptors drive Th   17 development and 
production of Th   17-related cytokines such as IL-17 have 
not yet been fully elucidated, they are considered to be 
essential factors for Th  17  development.
A role of cathepsin K in autoimmunity
Cathepsin K is a lysosomal cysteine protease that plays a 
pivotal role in osteoclast-mediated degradation of the 
bone matrices [84]. Th   us, cathepsin K has been 
considered a potential therapeutic target for the treat-
ment of bone diseases such as osteoporosis. We 
developed a new orally active cathepsin K inhibitor, 
NC-2300, and examined the eﬀ   ect of the inhibitor in 
osteoporosis as well as arthritis models [85]. We observed 
unexpected results that cathepsin K suppression leads to 
the reduction of inﬂ   ammation in the latter model. 
Cathepsin K, despite a low expression level in dendritic 
cells, plays an important role in the activation of Toll-like 
receptor (TLR) 9 signaling. CpG (cytosine followed by 
guanine) DNA (a TLR9 ligand)-induced production of 
cytokines such as IL-6 and IL-23 was found to be 
impaired in cathepsin K inhibitor-treated or cathepsin K-
deﬁ   cient dendritic cells. Th   e immune function of 
cathepsin K was further analyzed in EAE, and the severity 
of the disease was markedly suppressed in cathepsin K-
deﬁ  cient  mice.  Th  e suppression of inﬂ  ammation  was 
associated with the reduced induction of Th  17 cells, 
indicating that cathepsin K contributes to autoimmune 
inﬂ  ammation by inducing Th  17 cells, possibly through 
cytokines such as IL-6 and IL-23 in dendritic cells.
Th   e detailed mechanism by which cathepsin K 
regulates TLR9 signaling remains elusive, but it has been 
reported that functional maturation of TLR9 requires its 
proteolytic cleavage [86,87], to which cathepsin K might 
contribute. As cathepsin K is now known to be expressed 
by other cell types, including synovial cells [88], we 
cannot exclude the possibility that NC-2300 exerted an 
anti-arthritic eﬀ   ect through other cells. However, 
cathepsin K is an interesting example of a molecule that 
was originally found in bone and subsequently shown to 
regulate the immune system. Our study identiﬁ  ed 
cathepsin K as a novel dendritic cell-speciﬁ  c regulator of 
TLR9 signaling and as a potential target of therapeutic 
intervention into inﬂ  ammation-associated bone loss.
Regulation of Th17 development by IκBζ
We found that a nuclear IκB family member, IκBζ, was 
most highly expressed in Th  17 cells among the Th   cell 
subsets [89]. IκBζ is a nuclear protein highly homologous 
to Bcl-3, which interacts with the NF-κB subunit via the 
ankyrin repeat domain [90]. Its expression is rapidly 
induced by TLR ligands or IL-1 stimulation in peritoneal 
macrophages. Yamamoto and colleagues [91], using IκBζ-
deﬁ  cient mice, demonstrated that IκBζ is essential for the 
LPS induction of a subset of secondary response genes, 
including IL-6 and the IL-12 p40 subunit, in macro-
phages. However, no attempt to determine the function 
of IκBζ in T cells was reported in their study.
IκBζ expression was shown to be upregulated by the 
combination of IL-6 and TGF-β. IκBζ induction was 
mediated by Stat3, but not by RORγt, in Th  17 cells. 
Importantly, not only IκBζ-deﬁ  cient mice but also Rag2-
deﬁ   cient mice transferred with IκBζ-deﬁ  cient  CD4+ 
T cells were shown to be highly resistant to EAE. When 
naïve CD4+ T cells were activated in vitro under Th  1-  and 
Th  2-polarizing conditions, IκBζ-deﬁ   cient naïve CD4+ 
T cells normally produced IFN-γ and IL-4, respectively. 
On the other hand, when activated under Th  17-
polarizing conditions, IL-17 production in IκBζ-deﬁ  cient 
T cells was markedly reduced compared with wild-type 
T cells. Since the expression of RORγt and RORα was 
shown to be normal in IκBζ-deﬁ  cient T cells, it is unlikely 
that ROR nuclear receptors function downstream of IκBζ 
or vice versa.
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as essential regulators for Th   17 development as described 
above, several groups have reported that the ectopic 
expression of RORγt or RORα leads to only modest IL-17 
production in the absence of IL-6 and TGF-β [83,92]. Th  e 
ectopic expression of IκBζ in naïve CD4+ T cells did not 
induce IL-17 production in the absence of IL-6 and 
TGF-β. Interestingly, however, even in the absence of 
IL-6 and TGF-β, the ectopic expression of IκBζ, together 
with RORγt or RORα, potently induced IL-17 production. 
A reporter assay system showed that IκBζ moderately 
activated the promoter of the mouse Il17 gene as well as 
RORγt and RORα. When the ROR nuclear receptor was 
expressed, IκBζ highly activated the Il17 promoter. 
Previous studies showed that an evolutionarily conserved 
noncoding sequence 2 (CNS2) region in the Il17 locus is 
associated with histone H3 acetylation in a Th  17  lineage-
speciﬁ  c manner and that the ROR nuclear receptor is 
recruited to the CNS2 region during Th  17  development 
[83,93,94]. In combination with RORγt and RORα, IκBζ 
potently induced the CNS2 enhancer activity. IκBζ was 
recruited to the CNS2 region in Th   17 cells, and recruit-
ment of IκBζ to the CNS2 region was dependent on 
RORγt function (Figure 3). Moreover, the expression of 
IL-17F, IL-21, and IL-23 receptor was decreased in 
IκBζ-deﬁ  cient T cells. IκBζ also bound to the promoter or 
the enhancer region of these genes in Th  17 cells. 
Collectively, these ﬁ  ndings indicate that IκBζ is critical 
for the transcriptional program in Th  17 cell lineage 
commitment [89].
Conclusions
Th  e new ﬁ   eld of osteoimmunology originated from 
studies on bone destruction in RA. Increasing evidence 
has made it evident that the skeletal and immune systems 
are connected in complex ways; in fact, it would be 
diﬃ   cult to understand either system in depth without the 
insights aﬀ   orded by studying their interaction in an 
osteo  immunological context [44]. Th  e ﬁ   ndings in RA 
might be applicable to numerous inﬂ   am ma tory  or 
neoplastic diseases, such as periodontitis, infec  tious 
diseases, and primary or metastatic bone tumors.
Clearly, the Th   17 cell subset is an auspicious target for 
future therapeutic investigation, and cytokines related to 
Th  17 cell diﬀ  erentiation and function will be of great 
clinical importance. Antibodies against IL-17 or IL-23 
would be expected to exert beneﬁ  cial  eﬀ  ects in auto-
immune diseases, and antibodies targeting the IL-6 
receptor might not only inhibit Th   17 development in RA 
but also eﬀ  ect a direct inhibition of local inﬂ  ammation 
Figure 3. IκBζ and ROR nuclear receptors synergistically promote Th17 development. Interleukin (IL)-6 and transforming growth factor-β 
(TGF-β) induce Th17 cell diff  erentiation, in which the ROR nuclear receptors, RORγt and RORα, have an indispensable role. The expression of IκBζ 
is induced by the combination of IL-6 and TGF-β. IκBζ induction is mediated by signal transducer and activator of transcription 3 (Stat3), but not 
RORγt. IκBζ and ROR nuclear receptor bind directly to the CNS2 region of the Il17 promoter and cooperatively activate the Il17 promoter. Notably, 
recruitment of IκBζ to the CNS2 region was dependent on RORγt, suggesting that the binding of both IκBζ and ROR nuclear receptors to the Il17 
promoter leads to an effi   cient recruitment of transcriptional coactivators having histone acetylase activity. CNS2, conserved noncoding sequence 2; 
MHC II, major histocompatibility complex class II; ROR, retinoid-related orphan receptor; TCR, T-cell receptor; Th, helper T.
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Page 8 of 11and osteoclastogenesis [95,96]. Th  e mechanism of Th  17 
development is currently one of the most important 
subjects in immunology. In recent years, several trans-
criptional regulators of Th  17 development, including 
IRF4, BATF, Ahr, and Runx1, have been reported 
[92,93,97-99]. Although further studies will be required 
to determine whether or how IκBζ synergizes with other 
transcriptional regulators of Th   17 cells, our results raise 
the possibility that the targeting of IκBζ may prove 
eﬀ  ective in the treatment of autoimmune diseases.
Importantly, Th  17 cells are also implicated in host 
defense against a number of microorganisms. Inhibition 
of Th  17 cells might thus carry a risk of increasing the 
susceptibility to infection. Th  erefore, great care will be 
required to eﬀ  ectively treat autoimmune diseases without 
compromising the host defense system. Understanding 
the precise role of Th  17 cells in human autoimmune 
disorders therefore will be required for the development 
of eﬀ  ective therapeutic applications.
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